Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

136 results about "Azilsartan" patented technology

Azilsartan is an angiotensin II receptor antagonist used in the treatment of hypertension, developed by Takeda. It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN).

Azilsartan polymorphic substance and preparation method thereof

The invention provides an azilsartan polymorphic substance and a preparation method thereof. The azilsartan polymorphic substance is easy to separate and high in stability, has no hygroscopicity, and is an anhydrous polymorphic substance. The preparation method is simple, convenient and easy in industrial application.
Owner:JIANGSU SIMCERE PHARMA

Crystal form of azilsartan and preparation method thereof

The invention relates to a crystal form of azilsartan shown in formula (I) and a preparation method thereof, a pharmaceutical composition containing the crystal form, and an application of the crystal form or the pharmaceutical composition in preparing anti-hypertension medicaments.
Owner:JIANGSU HANSOH PHARMA CO LTD

Preparation method of Azilsartan tablets

The invention discloses a preparation method of Azilsartan tablets and belongs to the technical field of medicine. The preparation method comprises the following steps: 1, micronizing the Azilsartan, controlling D90 less than 15 micrometers, and conducting weighing according to formula dosage; 2, screening lactose monohydrate with a 60-mesh screen, and conducting weighing according to formula dosage; 3, screening a disintegrating agent and diluent with a 60-mesh screen respectively, and conducting weighing according to formula dosage; 4, mixing the auxiliary ingredients in the step 1, 2 and 3, adding solubilizer, conducting mixing, and screen the mixture with a 60-mesh screen; mixing the auxiliary ingredients uniformly, and adding adhesion agents for soft materials; conducting sieving, granulating, drying and arranging, adding lubricating agents, mixing the mixture uniformly, and tabletting. According to the preparation method, by controlling the particle diameter of the Azilsartan and the weight ratio between the Azilsartan and the lactose monohydrate and the varieties and adjusting the proportion of the disintegrating agents, the lubricating agents, the diluent, the solubilizer and the binding agents, the problem of dissolution rate can be solved, and the problem of external consistent dissolution is solved as well.
Owner:JIANGSU ZHONGBANG PHARMA

High-purity, small-particle-diameter and low-solvent-residue azilsartan bulk drug and preparation method thereof

The present invention discloses a high-purity, small-particle-diameter and low-solvent-residue azilsartan bulk drug and a preparation method thereof. The purity of the azilsartan bulk drug is more than or equal to 99.9%; the particle size of D90 is less than or equal to 20 [mu]m; and the solvent residue is less than or equal to 500 ppm. The present invention also discloses a high-purity intermediate used for preparing the azilsartan bulk drug and a preparation method thereof, wherein the purity of the intermediate is more than or equal to 99.9%.
Owner:珠海润都制药股份有限公司

Rivaroxaban tablets and preparation method for same

InactiveCN105078915ASolve the problem of slow disintegration and dissolutionUniform particle sizeOrganic active ingredientsPharmaceutical product form changeLACTITOL MONOHYDRATEDissolution
The invention provides rivaroxaban tablets and a preparation method for the same, and belongs to the field of pharmacy. Each rivaroxaban tablet is prepared from the following components in percentage by mass: 8.16 to 16.63 percent of rivaroxaban, 30.00 to 35.00 percent of lactose monohydrate, 41.56 to 48.94 percent of microcrystalline cellulose (ph101), 1.63 to 2.49 percent of sodium dodecyl sulfate, 2.08 to 3.26 percent of hydroxypropyl methyl cellulose, 3.32 to 4.9 percent of croscarmellose sodium and 0.49 to 0.67 percent of magnesium stearate. According to the novel rivaroxaban tablets and the internal and external disintegrant addition mixed-tabletting preparation method, croscarmellose sodium is internally and externally added, so that the problem of slow disintegration and dissolution of azilsartan tablets is solved; with adoption of a fluidized bed top-spraying granulation method, three procedures of mixing, granulation and drying in a conventional process are implemented by one step, so that production efficiency is improved, prepared granules are uniform in granularity and high in flowability and compression formability, and in addition, the problems of sticking, loosening and the like in a tabletting process are also solved.
Owner:JIANGSU ZHONGBANG PHARMA

Pharmaceutical composition for lowering blood pressure

The invention relates to a pharmaceutical composition containing azilsartan. The pharmaceutical composition particularly comprises azilsartan and at least one other antihypertensive medicine. The collaborative antihypertensive effect can be effectively played. The pharmaceutical composition for lowering blood pressure, which has a good antihypertensive effect, stable pressure reduction, and good tolerance, is provided.
Owner:JIANGSU CAREFREE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products